\-\ Texto\\:\\ \ \(0\)\
\-\ solitary\\ 1\\.4\\ cm\\ annular\\ eczematoid\\ plaque\\ on\\ right\\ shin\ \(0\)\
\-\ the\\ initial\\ lesion\\ resolved\\ with\\ ultra\\-potent\\ topical\\ steroids\\.\\ however\\,\\ over\\ the\\ next\\ 18\\ months\\,\\ groups\\ of\\ red\\-brown\\ papules\\ occurred\\ on\\ the\\ forehead\\ and\\ cheeks\\.\\ additional\\ biopsies\\,\\ tissue\\ cultures\\,\\ and\\ tb\\ complex\\ pcr\\ studies\\ continued\\ to\\ support\\ a\\ granulomatous\\ dermatitis\\ with\\ no\\ evidence\\ of\\ infection\\ or\\ foreign\\ bodies\\.\\ the\\ new\\ lesions\\ improved\\ with\\ topical\\ and\\ intralesional\\ steroids\\.\\ ophthalmologic\\ workup\\ has\\ shown\\ no\\ evidence\\ of\\ ocular\\ involvement\\.\ \(0\)\
\-\ tissue\\ culture\\ and\\ pcr\\ studies\\ negative\\ for\\ infectious\\ etiology\\.\ \(0\)\
\-\ histopathology\\:\\ the\\ biopsy\\ shows\\ several\\ naked\\ granulomas\\ without\\ birefringent\\ material\\ within\\ the\\ dermis\\.\\ acid\\ fast\\ and\\ fungal\\ stains\\ were\\ negative\\.\ \(0\)\
\-\ case\\ 4\\,\\ \\(27th\\ annual\\ uniformed\\ services\\ dermatology\\ conference\\,\\ 2003\\)\\ etanercept\\ induced\\ sarcoidal\\ granulomas\\ of\\ the\\ skin\ \(0\)\
\-\ \\â\\€\\¢neoplasms\ \(1\)\
\-\ \\â\\€\\¢infections\ \(1\)\
\-\ \\â\\€\\¢dermatitis\ \(1\)\
\-\ 76\\ y\\/o\\ asian\\ female\\ with\\ rheumatoid\\ arthritis\\ and\\ a\\ scaly\\ lesion\\ on\\ her\\ right\\ shin\\.\\ her\\ rheumatologist\\ started\\ her\\ on\\ etanercept\\ \\(25mg\\ sc\\ biw\\)\\ one\\ month\\ prior\\ to\\ the\\ initial\\ onset\\.\\ pmh\\:\\ s\\/p\\ 6\\ months\\ inh\\ treatment\\ for\\ pulmonary\\ scaring\\ on\\ cxr\\ consistent\\ with\\ prior\\ tb\\ infection\\;\\ \\(\\+\\)\\ bcg\\ vaccination\\.\ \(0\)\
\-\ Keywords\\ by\\ value\\:\\ \ \(0\)\
\-\ etanercept\\:\\ 0\\.07504266730148089\ \(0\)\
\-\ pcr\\:\\ 0\\.06394557347655049\ \(0\)\
\-\ topical\\:\\ 0\\.05878571869103543\ \(0\)\
\-\ shin\\:\\ 0\\.05829288874993006\ \(0\)\
\-\ granulomas\\:\\ 0\\.0553870092302151\ \(0\)\
\-\ eczematoid\\:\\ 0\\.04452282032306313\ \(0\)\
\-\ ultra\\-potent\\:\\ 0\\.04452282032306313\ \(0\)\
\-\ sarcoidal\\:\\ 0\\.04452282032306313\ \(0\)\
\-\ \\â\\€\\¢neoplasms\\:\\ 0\\.04452282032306313\ \(0\)\
\-\ \\â\\€\\¢infections\\:\\ 0\\.04452282032306313\ \(0\)\
\-\ \\â\\€\\¢dermatitis\\:\\ 0\\.04452282032306313\ \(0\)\
\-\ biw\\:\\ 0\\.04452282032306313\ \(0\)\
\-\ tb\\:\\ 0\\.041566040991657394\ \(0\)\
\-\ naked\\:\\ 0\\.04102207698690179\ \(0\)\
\-\ 25mg\\:\\ 0\\.04102207698690179\ \(0\)\
\-\ inh\\:\\ 0\\.04102207698690179\ \(0\)\
\-\ steroids\\:\\ 0\\.04060331190272482\ \(0\)\
\-\ red\\-brown\\:\\ 0\\.03897427341059793\ \(0\)\
\-\ birefringent\\:\\ 0\\.03897427341059793\ \(0\)\
\-\ scaly\\:\\ 0\\.03897427341059793\ \(0\)\
\-\ her\\:\\ 0\\.038930479674014175\ \(0\)\
\-\ bcg\\:\\ 0\\.037521333650740445\ \(0\)\
\-\ conference\\:\\ 0\\.0363943460178404\ \(0\)\
\-\ rheumatologist\\:\\ 0\\.035473530074436585\ \(0\)\
\-\ scaring\\:\\ 0\\.035473530074436585\ \(0\)\
\-\ ophthalmologic\\:\\ 0\\.0340205903145791\ \(0\)\
\-\ cheeks\\:\\ 0\\.03342572649813272\ \(0\)\
\-\ sc\\:\\ 0\\.03342572649813272\ \(0\)\
\-\ vaccination\\:\\ 0\\.03342572649813272\ \(0\)\
\-\ studies\\:\\ 0\\.0322373830078703\ \(0\)\
\-\ intralesional\\:\\ 0\\.03197278673827524\ \(0\)\
\-\ dermatitis\\:\\ 0\\.029924983161971386\ \(0\)\
\-\ stains\\:\\ 0\\.029392859345517715\ \(0\)\
\-\ 27th\\:\\ 0\\.02914644437496503\ \(0\)\
\-\ initial\\:\\ 0\\.028601839831104123\ \(0\)\
\-\ papules\\:\\ 0\\.028067787302752608\ \(0\)\
\-\ forehead\\:\\ 0\\.028067787302752608\ \(0\)\
\-\ asian\\:\\ 0\\.028067787302752608\ \(0\)\
\-\ biopsies\\:\\ 0\\.027877179585667523\ \(0\)\
\-\ groups\\:\\ 0\\.02769350461510755\ \(0\)\
\-\ dermis\\:\\ 0\\.02769350461510755\ \(0\)\
\-\ 1\\.4\\:\\ 0\\.02751627572717184\ \(0\)\
\-\ fast\\:\\ 0\\.027345055769213852\ \(0\)\
\-\ annular\\:\\ 0\\.02671291868358756\ \(0\)\
\-\ ocular\\:\\ 0\\.026151173051717744\ \(0\)\
\-\ plaque\\:\\ 0\\.02601998372644875\ \(0\)\
\-\ induced\\:\\ 0\\.025892116009356373\ \(0\)\
\-\ negative\\:\\ 0\\.025778991529039137\ \(0\)\
\-\ acid\\:\\ 0\\.025297252192909996\ \(0\)\
\-\ infection\\:\\ 0\\.02509107650578593\ \(0\)\
\-\ 76\\:\\ 0\\.024376436249506184\ \(0\)\
\-\ histopathology\\:\\ 0\\.02410336947541388\ \(0\)\
\-\ uniformed\\:\\ 0\\.0237608311100666\ \(0\)\
\-\ months\\:\\ 0\\.023575164592828966\ \(0\)\
\-\ services\\:\\ 0\\.023286999013007743\ \(0\)\
\-\ dermatology\\:\\ 0\\.023286999013007743\ \(0\)\
\-\ support\\:\\ 0\\.02313844403721838\ \(0\)\
\-\ culture\\:\\ 0\\.022994134075379712\ \(0\)\
\-\ occurred\\:\\ 0\\.0228538332465561\ \(0\)\
\-\ evidence\\:\\ 0\\.022630733165322\ \(0\)\
\-\ \\+\\:\\ 0\\.0222666625085972\ \(0\)\
\-\ cultures\\:\\ 0\\.022205443516009598\ \(0\)\
\-\ workup\\:\\ 0\\.022205443516009598\ \(0\)\
\-\ prior\\:\\ 0\\.02216275527477135\ \(0\)\
\-\ next\\:\\ 0\\.021910008128728748\ \(0\)\
\-\ 2003\\:\\ 0\\.0216855042773609\ \(0\)\
\-\ annual\\:\\ 0\\.02163090369097597\ \(0\)\
\-\ pmh\\:\\ 0\\.021470556729791226\ \(0\)\
\-\ solitary\\:\\ 0\\.02141821942153089\ \(0\)\
\-\ foreign\\:\\ 0\\.021264385040294983\ \(0\)\
\-\ resolved\\:\\ 0\\.020922674694467635\ \(0\)\
\-\ fungal\\:\\ 0\\.020922674694467635\ \(0\)\
\-\ granulomatous\\:\\ 0\\.020829144150188664\ \(0\)\
\-\ improved\\:\\ 0\\.02055851664446085\ \(0\)\
\-\ tissue\\:\\ 0\\.020458799883359535\ \(0\)\
\-\ rheumatoid\\:\\ 0\\.020385832984116004\ \(0\)\
\-\ bodies\\:\\ 0\\.020218858932293336\ \(0\)\
\-\ material\\:\\ 0\\.019284374495971635\ \(0\)\
\-\ started\\:\\ 0\\.01925036423242949\ \(0\)\
\-\ 18\\:\\ 0\\.018735216919524837\ \(0\)\
\-\ continued\\:\\ 0\\.01858444437836483\ \(0\)\
\-\ infectious\\:\\ 0\\.01855482256294868\ \(0\)\
\-\ arthritis\\:\\ 0\\.018438042676984772\ \(0\)\
\-\ on\\:\\ 0\\.01828007606983404\ \(0\)\
\-\ etiology\\:\\ 0\\.018267784811619562\ \(0\)\
\-\ cxr\\:\\ 0\\.018212284197601403\ \(0\)\
\-\ s\\/p\\:\\ 0\\.018103079833898545\ \(0\)\
\-\ lesion\\:\\ 0\\.017581365919196512\ \(0\)\
\-\ additional\\:\\ 0\\.017305286334090897\ \(0\)\
\-\ shown\\:\\ 0\\.017305286334090897\ \(0\)\
\-\ complex\\:\\ 0\\.017282277159667358\ \(0\)\
\-\ skin\\:\\ 0\\.016576408763833223\ \(0\)\
\-\ involvement\\:\\ 0\\.01581787200317079\ \(0\)\
\-\ biopsy\\:\\ 0\\.015311582028468489\ \(0\)\
\-\ new\\:\\ 0\\.015039333216164437\ \(0\)\
\-\ several\\:\\ 0\\.01387420624102216\ \(0\)\
\-\ onset\\:\\ 0\\.013623339524874496\ \(0\)\
\-\ month\\:\\ 0\\.012947548185861664\ \(0\)\
\-\ 6\\:\\ 0\\.012889495764519568\ \(0\)\
\-\ pulmonary\\:\\ 0\\.012608839950606382\ \(0\)\
\-\ 4\\:\\ 0\\.0120251106322174\ \(0\)\
\-\ however\\:\\ 0\\.012017010381803387\ \(0\)\
\-\ y\\/o\\:\\ 0\\.011952671867775964\ \(0\)\
\-\ shows\\:\\ 0\\.011865523736004439\ \(0\)\
\-\ one\\:\\ 0\\.011695613047023457\ \(0\)\
\-\ cm\\:\\ 0\\.011575535948570637\ \(0\)\
\-\ lesions\\:\\ 0\\.011553335890626\ \(0\)\
\-\ \\:\\:\\ 0\\.011416917333239041\ \(0\)\
\-\ over\\:\\ 0\\.010988093889595771\ \(0\)\
\-\ \\(\\:\\ 0\\.010944874640058493\ \(0\)\
\-\ \\)\\:\\ 0\\.010811177153231896\ \(0\)\
\-\ consistent\\:\\ 0\\.010582314489046481\ \(0\)\
\-\ \\;\\:\\ 0\\.010229399941679767\ \(0\)\
\-\ without\\:\\ 0\\.010161682658374548\ \(0\)\
\-\ were\\:\\ 0\\.00979942594287839\ \(0\)\
\-\ case\\:\\ 0\\.009441941580137732\ \(0\)\
\-\ right\\:\\ 0\\.00910739100111532\ \(0\)\
\-\ female\\:\\ 0\\.008872526623473908\ \(0\)\
\-\ treatment\\:\\ 0\\.00873543918990347\ \(0\)\
\-\ no\\:\\ 0\\.008691355057614163\ \(0\)\
\-\ within\\:\\ 0\\.008232986911040817\ \(0\)\
\-\ \\,\\:\\ 0\\.008203335318705679\ \(0\)\
\-\ has\\:\\ 0\\.008104545305526657\ \(0\)\
\-\ for\\:\\ 0\\.00736472877416884\ \(0\)\
\-\ the\\:\\ 0\\.005585829684994982\ \(0\)\
\-\ and\\:\\ 0\\.005454818355521771\ \(0\)\
\-\ or\\:\\ 0\\.005058195701836907\ \(0\)\
\-\ to\\:\\ 0\\.004313819277201882\ \(0\)\
\-\ a\\:\\ 0\\.004006058604228296\ \(0\)\
\-\ with\\:\\ 0\\.002954650911360852\ \(0\)\
\-\ of\\:\\ 0\\.0023536121373331\ \(0\)\
\-\ \\.\\:\\ 0\\.001972196449852571\ \(0\)\
